ReviewThe Lancet. Global health2026
Beyond malaria: can intermittent preventive treatment with sulphadoxine-pyrimethamine reduce the number of small vulnerable newborns globally?
Review in The Lancet. Global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of Prenatal Nutrition Interventions on Infant Longitudinal Growth: A Secondary Analysis of the Mumta Pregnant Women Trial in Pakistan.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Evidence and opportunities for preeclampsia and cardiovascular disease prevention in malaria endemic settings.Communications medicine · 2026Review
- Indirect benefits of seasonal malaria chemoprevention for non-malarial pediatric infections and routine antibiotic use in real-world programmatic settings: a pre-post study using positive and negative controls.BMC infectious diseases · 2026Article
- Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Efforts to reduce the global burden of small vulnerable newborns (SVNs) by scaling up existing preventive interventions must be complemented with new preventive approaches to achieve global targets. Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) was originally designed to protect pregnant women from malaria infection, but appears to retain efficacy against low birthweight even when Plasmodium infection is absent or the parasite is highly resistant to sulphadoxine-pyrimethamine. This specific effect might occur through the antimicrobial activity of sulphadoxine-pyrimethamine against maternal genitourinary tract infections and pathogenic gut bacteria, direct effects on maternal gut physiology that might reverse environmental enteric dysfunction, or anti-inflammatory actions. Refining our understanding of the pathways underlying the protective efficacy of sulphadoxine-pyrimethamine will require mechanistic studies and placebo-controlled randomised trials of IPTp-SP in non-malarious settings. These studies will be crucial to confirm whether sulphadoxine-pyrimethamine could be considered for reducing the risk of SVNs in settings with high prevalence of SVNs and little or no malaria transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.